Combination targeted therapy for CLL
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at MD Anderson. Findings from the single-institution Phase II study were published in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.